• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.

作者信息

Kawada Tomoyuki

机构信息

Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.

出版信息

J Cardiol. 2017 Jul;70(1):99. doi: 10.1016/j.jjcc.2016.12.017. Epub 2017 Feb 13.

DOI:10.1016/j.jjcc.2016.12.017
PMID:28209462
Abstract
摘要

相似文献

1
Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.新型口服抗凝药与华法林治疗非瓣膜性心房颤动患者的疗效及风险
J Cardiol. 2017 Jul;70(1):99. doi: 10.1016/j.jjcc.2016.12.017. Epub 2017 Feb 13.
2
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.低剂量非维生素K拮抗剂口服抗凝药与华法林在房颤患者中的有效性和安全性：倾向评分加权的全国队列研究
BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510.
3
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
4
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.在美国，利伐沙班、达比加群和华法林用于非瓣膜性心房颤动患者预防卒中的治疗持续性和停药情况。
PLoS One. 2016 Jun 21;11(6):e0157769. doi: 10.1371/journal.pone.0157769. eCollection 2016.
5
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.达比加群、利伐沙班和华法林导致胃肠道出血的比较风险：基于人群的队列研究。
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
6
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.口服抗凝剂治疗非瓣膜性心房颤动患者的大出血风险：真实世界观察性研究的系统评价
Curr Med Res Opin. 2017 Sep;33(9):1583-1594. doi: 10.1080/03007995.2017.1347090. Epub 2017 Jul 6.
7
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.口服抗凝剂在新诊断房颤老年患者中的性别特异性比较疗效
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
8
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.非瓣膜性心房颤动且既往有卒中和短暂性脑缺血发作患者中应用阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
Stroke. 2017 Aug;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474. Epub 2017 Jun 27.
9
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.在美国医疗保险人群中，与华法林相比，起始使用阿哌沙班、达比加群或利伐沙班的非瓣膜性心房颤动患者发生中风/全身性栓塞、大出血及相关费用的风险。
Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11.
10
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.阿哌沙班、达比加群和低剂量利伐沙班与华法林相比在日本非瓣膜性心房颤动患者中的出血风险：基于行政索赔数据的倾向匹配分析
Curr Med Res Opin. 2017 Nov;33(11):1955-1963. doi: 10.1080/03007995.2017.1374935. Epub 2017 Sep 12.

引用本文的文献

1
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
J Cardiol. 2017 Jul;70(1):99-100. doi: 10.1016/j.jjcc.2017.02.003. Epub 2017 Mar 18.